Clinical Trials Browser

Withdrawn × Bevacizumab × Thoracic × Clear all

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05180422 2023-10-18

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00469976 2015-10-08

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00755157 2015-10-07

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Phase 2 Withdrawn

Neoplasms, Small Cell Lung Carcinoma

NCT01674738 2013-10-11

SELECT-A

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00411593 2012-02-08

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms